From: TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
RR | 95 percent CI | P | RR | 95 percent CI | P | |
Age, ≥55 years versus <55 years | 0.86 | 0.51–1.44 | 0.57 | |||
Tumor type (overall effect) | 0.14 | |||||
Lobular (versus ductal) | 0.56 | 0.30–1.06 | 0.074 | |||
Other (versus ductal) | 0.66 | 0.26–1.67 | 0.38 | |||
Tumor size (overall effect) | 0.001 | 0.002 | ||||
pT2 (versus pT1) | 2.22 | 1.17–4.20 | 0.014 | 1.94 | 0.99–3.82 | 0.054 |
pT3–pT4 (versus pT1) | 4.17 | 1.93–9.01 | 0.0003 | 4.44 | 1.95–10.1 | 0.0004 |
Lymph node status (overall effect) | 0.035 | 0.027 | ||||
pN1 (versus pN0) | 1.34 | 0.69–2.62 | 0.39 | 1.09 | 0.54–2.21 | 0.81 |
pN2–pN3 (versus pN0) | 3.42 | 1.82–6.41 | 0.0001 | 2.73 | 1.41–5.30 | 0.003 |
Othera (versus pN0) | 1.69 | 0.77–3.67 | 0.19 | 1.28 | 0.51–3.20 | 0.60 |
Histological grade (overall effect) | 0.47 | |||||
G2 (versus G1) | 0.99 | 0.39–2.50 | 0.98 | |||
G3 (versus G1) | 1.43 | 0.52–3.90 | 0.49 | |||
TP53 mutation (versus wild type) | 4.51 | 2.69–7.56 | <0.0001 | 5.24 | 3.03–9.07 | <0.0001 |
ER positive (versus negative) | 0.72 | 0.43–1.22 | 0.23 | |||
PR positive (versus negative) | 0.82 | 0.49–1.36 | 0.44 |